440 related articles for article (PubMed ID: 27574190)
1. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy.
Cheson BD; Ansell S; Schwartz L; Gordon LI; Advani R; Jacene HA; Hoos A; Barrington SF; Armand P
Blood; 2016 Nov; 128(21):2489-2496. PubMed ID: 27574190
[TBL] [Abstract][Full Text] [Related]
2. Rethinking clinical response and outcome assessment in a biologic age.
Cheson BD
Curr Oncol Rep; 2015 Jun; 17(6):27. PubMed ID: 25975729
[TBL] [Abstract][Full Text] [Related]
3.
Tamayo P; Martín A; Díaz L; Cabrero M; García R; García-Talavera P; Caballero D
Rev Esp Med Nucl Imagen Mol; 2017; 36(5):312-321. PubMed ID: 28483374
[TBL] [Abstract][Full Text] [Related]
4. Staging and response assessment in lymphomas: the new Lugano classification.
Cheson BD
Chin Clin Oncol; 2015 Mar; 4(1):5. PubMed ID: 25841712
[TBL] [Abstract][Full Text] [Related]
5. Staging of lymphoma under chimeric antigen receptor T-cell therapy: reasons for discordance among imaging response criteria.
Winkelmann M; Blumenberg V; Rejeski K; Bücklein VL; Ingenerf M; Unterrainer M; Schmidt C; Dekorsy FJ; Bartenstein P; Ricke J; von Bergwelt-Baildon M; Subklewe M; Kunz WG
Cancer Imaging; 2023 May; 23(1):44. PubMed ID: 37189191
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of Lymphoma and Myeloma: Facts and Hopes.
Pianko MJ; Moskowitz AJ; Lesokhin AM
Clin Cancer Res; 2018 Mar; 24(5):1002-1010. PubMed ID: 28899972
[TBL] [Abstract][Full Text] [Related]
7. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E; Younes A
Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
[TBL] [Abstract][Full Text] [Related]
8. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
9. Current studies of immunotherapy in head and neck cancer.
Dogan V; Rieckmann T; Münscher A; Busch CJ
Clin Otolaryngol; 2018 Feb; 43(1):13-21. PubMed ID: 28464441
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Response to Immunotherapy in Patients with Hodgkin Lymphoma: Towards Quantifying Changes in Tumor Burden Using FDG-PET/CT.
Tutino F; Giovannini E; Chiola S; Giovacchini G; Ciarmiello A
J Clin Med; 2023 May; 12(10):. PubMed ID: 37240602
[TBL] [Abstract][Full Text] [Related]
11. Immune-Mediated Therapies in Lymphoma.
Forbes SG; Mistry HE
Semin Oncol Nurs; 2019 Oct; 35(5):150925. PubMed ID: 31526549
[TBL] [Abstract][Full Text] [Related]
12. Lymphoma Microenvironment and Immunotherapy.
Xu ML; Fedoriw Y
Surg Pathol Clin; 2016 Mar; 9(1):93-100. PubMed ID: 26940270
[TBL] [Abstract][Full Text] [Related]
13. Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome.
Araujo B de Lima V; Borch A; Hansen M; Draghi A; Spanggaard I; Rohrberg K; Reker Hadrup S; Lassen U; Svane IM
Cytotherapy; 2020 Apr; 22(4):204-213. PubMed ID: 32201034
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial.
Trotman J; Barrington SF; Belada D; Meignan M; MacEwan R; Owen C; Ptáčník V; Rosta A; Fingerle-Rowson GR; Zhu J; Nielsen T; Sahin D; Hiddemann W; Marcus RE; Davies A;
Lancet Oncol; 2018 Nov; 19(11):1530-1542. PubMed ID: 30309758
[TBL] [Abstract][Full Text] [Related]
15. Modification of Lugano criteria by pre-infusion tumor kinetics improves early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy.
Winkelmann M; Blumenberg V; Rejeski K; Quell C; Bücklein V; Ingenerf M; Unterrainer M; Schmidt C; Dekorsy FJ; Bartenstein P; Ricke J; von Bergwelt-Baildon M; Subklewe M; Kunz WG
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37880181
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulators in Lymphoma.
Anagnostou T; Ansell SM
Curr Treat Options Oncol; 2020 Mar; 21(4):28. PubMed ID: 32193838
[TBL] [Abstract][Full Text] [Related]
17. Checkpoint blockade in lymphoma.
Armand P
Hematology Am Soc Hematol Educ Program; 2015; 2015():69-73. PubMed ID: 26637703
[TBL] [Abstract][Full Text] [Related]
18. Next-generation immunotherapies for lymphoma: one foot in the future.
Manson G; Houot R
Ann Oncol; 2018 Mar; 29(3):588-601. PubMed ID: 29365060
[TBL] [Abstract][Full Text] [Related]
19. Immune-Checkpoint Blockade Therapy in Lymphoma.
Kuzume A; Chi S; Yamauchi N; Minami Y
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751706
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors and cellular treatment for lymphoma immunotherapy.
Li F; Chen Y; Pang M; Yang P; Jing H
Clin Exp Immunol; 2021 Jul; 205(1):1-11. PubMed ID: 33675535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
